Frontal lobe d ysfuncti on in sch izo p h ren ic pa tients h as b een high ly suspected for man y yea rs. Man y psychia trists a nd patie nts, however, a re awai ti ng so lid p roof of a biological manifesta tion of th is disease. While positron emissio n tomograph y does not uni forml y d emonstrate suc h a ma ni festa tio n , it does d emonstrate a prefrontal co rtex d eficit in most r eported stud ies . Furthe r , a locali zati on o f the a ttention d eficit of sch izo p hrenia, in the prefrontal co r tex, is str o ngly suggeste d b y so me stud ies.
I NTROD UC TION
Positron e miss io n tomograph y (PET) h as e na b led investigators in mod e rn clin ica l psychiat r y to demonstrate that schizop h ren ia is, at least in part, a frontal lobe di sorder. PET studies o f man y pati ents with sch izo p hren ia e xh ibit a d ecrea sed le vel of metaboli sm in the frontal cortex. O th er brain areas hav e also been in vestigat ed fo r th ei r rol e in sc h izo p h ren ia. T hese regions include t he hippocampus ( I), ba sal ganglia, limbic system, a n d other brainstem areas (2) . This re view , however, is limited to the d eficit most co nsis te n t ly reported with PE T brain metaboli sm stud ies-hy pofron ta lity .
Frontal lobe d ysfunction in schizoph re n ia has bee n suggested fo r many years by several research parad igms. Post-mortem studies ha ve reported abno rmal neurotransmitter rece p tor levels including se rotonergic (3, 4) , muscarinic (5) , GABAergic (6), and others. Histologi cal a b nor malit ies in the frontal co rt ex of schizop hren ic p ati e nts, in clu di ng d ecreased cortical cells (neurons > glia) in la ye r VI (7) a nd ultrastructural (EM) a b nor ma lit ies in neurons (8) , ha ve bee n reported. Frontal lobe pathology has a lso been suggested by MRI studies, reportin g sign ifica ntly sm all e r frontal lobes in schizop hren ics (9) . Cogniti ve aspects of sch izo p h re n ia, includi ng a ttentio n a nd vigi lance, have been a co n t inuing foc us in th e evalua tio n o f this di sease ( 10, II ). A recent study of patients with fr o n ta l lobe lesions d emonstrated that these pati ents also had a de ficie ncy in maintaining tasks that require sus ta ined attention (12) . Fr o ntal lo be d ysfunct io n in sc hizop h re nia has, th erefore , been str o ngly suggested from several research paradigms. Recentl y, however, a locali zation o f this d eficit in a specific b rain region has been demonstrated b y funct ional imaging techniques.
Early functional imaging stud ies of cerebral metabolism uti lized Xe [1 33 ] inhalation or carotid injection to examine relative blood flow rates. Ingva r and Frazen applied this technology to the study of schizoph renic patient s and demonstrated a relative decrease in ce re b ral blood flow in th ese patients (13 ,1 4). They reported that normal persons d emonstrated a relativel y higher b lood flo w in th e prefrontal cortex than in temporal o r parietal co r t icies. In schizophrenic patients, however, this h yperfrontal it y was attenua te d a nd th e patients were described as hypofr ontal. A review o f atte mp ts to replicat e these findin gs is available (15) . Cerebral blood flow stud ies using Xe [1 33 ] , ho wever , have seve ral limitations, including lower spatial resolution and p ro visio n of on ly relative blood flow values. PET scan technology has been useful in co nfirming, and investigating more effectively, h ypofrontality in schizop h ren ia. Recent advances in co n tro lling the behavioral aspects of the scanning procedure and evidence of a more precise localization of the d ysfunction in th e mid-pre fro n tal cortex may permit significant advances in th e understanding of schizop hrenia (16) .
PET TECHNOLOGY
PET sca n ning utilizes shor t lived, radioacti vel y label ed bio molecules to study normal and dis eased states in brain tissues. A positron e mi tt ing isotope is incorporated into metabolites, or drugs, by using a cyclo tron wh ich forms an unstable nucleus. Within the nucleus of the isotope, a proton tran sfo rms into a neutron . During this transformation, a positron is em itted . T he posit ro n then collides with an electron to produce two photons of light. A geometr ica l image of relati ve photon activity is then developed. A d etailed revie w of PET technology is available (17 ) .
One o f the most useful compounds in psychiatric research has been F[ 18 ]-labeled 2 f1ouro-2-deoxy-D glucose (FDG). The FDG tracer meth od , developed by Sokoloff, Re ivich and coworkers (18) (19) (20) , has been used to evaluate glucose metabolism in brain tissues. According to their 2-d eoxyglucose model , FDG is transported into the cell and phosphorylated in a manner simi lar to glucose . However, unlike glucose, phosphorylated FDG is not a subst rat e for meta boli sm . Once transported into the cell , FDG is phosphorylated and d egraded slowl y enough to be considered essentially trapped during th e sca n n ing measu reme nt s. FDG is phosphorylated (the rate limiting step) ba sed on metabol ic needs and is, therefore, a good indicator of cellular ac tivity . The fu nc t io nal imaging offered by PE T o pens new dimensions in the study of brain physiol ogy. Although co nv e n tio na l imaging with x-ray technology ha s e na b led visua liza tion of structural changes (eg. ventricular enlargement) in schizop hrenia, PET may detect biochemical changes at an earlier stage and provide more information about th e pathophysiology. Symbols: SIC -Schizophrenic pa tie nts/ co nt ro l subjects; * o n ly stu dy r eportin g decreased frontal rate, ye t increased A :P ratio; n .r. -not r epo r ted. Notes: I) All studies used age-matched controls except Buchsbaum , 1984 (q ua druplet study -ages 51); Wolkin, 1985 (mean ages sic -38 /27). Brodie , 1984 , d id not report ages. All remaining st udies reported mean ages of22-38 . 2) Frontal metabolism differences include reported differences in a bso lu te frontal rates; fronta l: whole slice, fronta l: whole brain or anterior:posterior ratios. 3) A ll stu dies u sed glucose ligand s excep t Sheppard, 1984 (O[ 15 ] and C[ 15]02).
DEM ONSTRATION O F HYPOFRONTALITY BY PET
A search of P ET literature reporting on frontal lobe gluco se metaboli sm in schizophren ic patients u nco ve r ed approximately thirty studies . The first P ET rep o r t of h yp om e ta bo lic activity in the frontal cortex of a sch izop hren ic pati e nt was b y Farkas, Re ivich and coworkers in 1980 (21) . Other ea rly stu dies by Buchsba u m (22) and Wi den (23) confirmed the evidence of h ypo fr ontal ity. St udies usin g medicated schizophrenic patients have generally d emonst ra ted h yp ome taboli c ac tiv ity in the frontal cortex (24) (25) (26) (27) (28) . Table I , above , ho we ve r , presents a review of 2 1 studies using only unmedicated and nev er medicated patients, due to a concern of possible confounding effec t b y neu roleptic treatment . Re vie w of these stud ies revea ls some inconsistent findin gs. Se ve ral vari-abies have been co nside red as possible sources for th e discrepa ncy between these findings.
The variable which has received the most discussion in t he lite ra tu re has been neuroleptic treatment. Some investigators h av e questio ned the va lidity of reports of h ypometabolic activity in the frontal cortex of schizoph re n ics because of neuroleptic treatment concurrent with or preceding sca n n ing p r oced u res (30 ,4 1) . These investigators suggest that h ypofrontal ity find in gs may be an effect of treatment and not a manefestation of schizophren ia. T h is view is partly su pp o rted by findings of extended clinical and pharmacokineti c effects which persist following termination of medication (4 8, 49) . Additional support for their viewpoint comes from studies of never-medicated schizophrenics (30,3 1,40,41 ). These studies have consistently found no sign ifica nt differences in fronta l lobe metabolism in schizophrenic patients. Howe ver, these findi ngs may be due to a biological difference between new-onset and chronic sch izo p hrenia. A recent report by Wiessel and coworkers (43) indicated that duration of illness was directl y correlated with degree ofhypofrontality.
Due to the concern of possible frontal lobe ch a nges wit h ne ur ol e p tic treatment, most studies have utilized patients whi ch have been tak en off medication prior to th e scanning procedure (wash-out studies). Of th e recent studies using non medicated patients (see table) , most have used patients o ff ne u rol e p tics fo r at least 13 days. Some studies have used wash-out periods of o n ly 10 da ys (44, 4 5) . Others have used m ixed samples with so me patie nts tha t rece ived limited dosages at least forty-eight hours prior to scanning (30) or so me pat ie nts off neuroleptics for at least seven days (42) . One study did not specify durat io n off medication (22) .
Support for the validity of studies reporting h ypofrontality in pa tie nts unmedicated prior to and during scanning procedures ca n be fo und in the reports of PET studies comparing metabolism before a nd during ne u role ptic treatment. These reports have generally indicated that fr o n tal glucose me tab olism is either unchanged or increased, not decreased, during neurole p tic treatm ent (38-40 ,50-53) . Changes in metabolism were stud ied with med ica tio n intervals ranging from 1 hour to 7.4 yea rs. Further support for th e va lidity of studies using previousl y medicated patients comes fr om d opami ne rece ptor occupancy studies. Using Br[76] labeled b romosp iperone b indin g to corpus striatum , Camdon and coworkers (54) found that after neuroleptic wit hdrawal, a return to 100% unoccupied receptors oc curred within 7-12 da ys in the majority (6/ 8) of subjects tested. A final a nswe r to this quest ion of neu r ol eptic effects on frontal lobe metabolism ma y require a prospective study o f metaboli c rates before, during and foll owing neuroleptic treatment, whi ch d emo nstra tes a co m p le te return to ba seline metabolism.
One va r ia b le of increasingl y apparent importance, whi ch remains less than o p t im ally co n tr o lled in most experiments to d at e , is beha vio ral activity during PET scanning. Most studies of metabolic activity have used resting subjects. Many stud ies have taken measures to limit se ns o ry st im u lation of t he patient during scanning in order to provide a more uniform sensory e nvi ronment. Other studies have used somatosensory stimuli in the form o f mild electrica l shock to the right forearm (33, 34, 36, 50) . Somatosensory stimuli h ave b ee n used to maintain a uniform sensory environment between subjects and preferentiall y activate the frontal lobes (55, 56) . Xe [133] blood flow studies h ave repo rted attenuation of this activation in schizophrenic subjects (57) . Howev e r , a rece n t PET study comparing sensory environments during scanning found that somatosensory stimulation is not an effective method of frontal cortex acti vatio n (58). In a study of 52 normal volunteers. Cohen and co-workers compared the effects of somatosensory stimulation , auditory discrimination a nd resting sta tes on frontal metabolic activity. Increased metabolic rates were found in th e r ight middle prefrontal cortex during the auditory discrimination task. This incr eased rate demonstrated a direct correlation with the accuracy of the subjects' perfo rmance, suggesting that this area may be very important in attention maintenance. The somatosensory stimuli, however, was not associated with generali zed activation of the frontal cortex.
Continuous performance tasks, such as the auditory di scrimination task , have also been used to study the attention deficits in schizophrenia. Conti nuo us performance tasks have been shown to be highly sensitive to functi onal illness (59) and have been used to demonstrate attention deficits in sch izo phrenia (60) . Their attention deficit is evident in several areas. They o ft en fail to a ttend to novel stimuli (6 I). Once attention is attained, they often fail to ma intai n task performance. The fronallobe appears to be involved in anticipator y responding. The fronal lobe deficit theory of schizophrenia, therefore, is supported by th e patient's poor preparation for response. A study by Cohen (16) examining 16 schizophrenic patients, performing auditory discrimination tasks durin g PET scanning, demonstrated specific areas of deficient metabolism . O f the 55 specific regions examined, only the left anterior, medial and right anterior areas of th e frontal cortex, in a single plane, demonstrated significant metabolic d e ficits. An earlier study by Jernigan and co-workers (37) also used an a ud itory d iscr im ination task to study schizophrenic patients. Their finding of nonsignifica nt cha nges, however, may have been due to a limited sample size (6 pati ents) or th e lim ited number of slices analyzed (I slice).
CONCLUSIONS
Greater than 50% of the PET studies investigating fr ontal lobe me ta bo lism have demonstrated decreased activity in schizophrenic patients. The va r iab ilit y of findings in the frontal cortex do not appear to be caused by neur ol e ptic medi cation. However, a prospective study of neuroleptic effec ts before , during and after medication may be useful. Some authors h a ve suggeste d that the failure to consistently confirm frontal deficits may be due to different pa th ol ogical groups of schizophrenics (eg. frontal and temporal lesions). O the rs have suggested that variance between studies may reflect the chro nicity o f th e d isease .
Additional sources of variance may include specificit y of a nalysis (eg. whole frontal cortex slice vs. subdivided areas) and sample size. Frontal cortex ac tivating ta sks may also reduce the variability between studies by utilizing the recognized attention deficit seen in most of these patients.
In summary, an area of metabolic dysfunction in the prefrontal co rtex of schizophrenic patients has been demonstrated through th e use of posit ro n emission tomography. The inconsistencies in the attempts to r eplicat e th ese findings are probably due to multiple variables. The fact th a t 50 % of the stud ies have succeeded in demonstrating a frontal lobe deficit is rema rk able , given th e lack of frontal activating tasks and limited subdivision of frontal a reas in most studies.
In conclusion, PET technology is opening new dim ensions to th e study of psychiatric research. PET offers functional imaging not pro vid ed b y previou s analytical instruments and greater precision and depth than o ther ne wly de veloped techniques. Further refinement of nuclear and computer technol ogy, and experimental methodology promise to make PET an inv aluable tool in the study of schizophrenia and other mental diseases.
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